Want to see IN:LOTUSEYE full AI Analyst Report?
LOTUSEYE Stock Chart & Stats
₹118.10
-₹0.92(-1.30%)
At close: 4:00 PM EST
₹118.10
-₹0.92(-1.30%)
Day’s Range― - ―
52-Week Range₹87.44 - ₹153.00
Previous CloseN/A
Volume15.88K
Average Volume (3M)2.23K
Market Cap
₹2.42B
Enterprise Value₹2.50K
Total Cash (Recent Filing)₹38.27M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)1445.0
Beta0.84
Next Earnings
Nov 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.08
Shares Outstanding20,796,330
10 Day Avg. Volume4,541
30 Day Avg. Volume2,230
Financial Highlights & Ratios
PEG Ratio-27.83
Price to Book (P/B)3.28
Price to Sales (P/S)3.68
P/FCF Ratio-18.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthSustained revenue growth indicates continuing demand for the company’s ophthalmology consultations, diagnostics and procedures. This provides a durable base for recovery if cost control and operating execution improve.
Equity-Supported Balance SheetThe substantial equity base relative to debt gives Lotus Eye a degree of balance-sheet support and financial resilience. It can help the company fund operations and investments while reducing dependence on external financing.
Positive Operating Cash FlowPositive operating cash flow shows that the core healthcare business still converts patient-service activity into cash. Although modest, this offers an internal funding source and supports ongoing clinical operations.
Bears Say
Severe Profitability DeteriorationNear-zero net profitability and a negative operating margin leave little buffer against cost increases or weaker demand. Unless margins recover, revenue growth may not translate into stronger earnings or sustainable shareholder returns.
Deeply Negative Free Cash FlowRepeatedly negative free cash flow suggests reinvestment and/or working-capital needs exceed internally generated funds. This can increase funding requirements and constrain the company’s ability to expand without additional financing.
Rapidly Rising LeverageThe sharp increase in leverage raises financial risk while earnings and cash generation are weak. Higher debt commitments could reduce flexibility and make future expansion more difficult if profitability fails to rebound.
Lotus Eye Hospital And Institute Ltd News
LOTUSEYE FAQ
What was Lotus Eye Hospital And Institute Ltd’s price range in the past 12 months?
Lotus Eye Hospital And Institute Ltd lowest stock price was ₹87.44 and its highest was ₹153.00 in the past 12 months.
What is Lotus Eye Hospital And Institute Ltd’s market cap?
Lotus Eye Hospital And Institute Ltd’s market cap is ₹2.42B.
When is Lotus Eye Hospital And Institute Ltd’s upcoming earnings report date?
Lotus Eye Hospital And Institute Ltd’s upcoming earnings report date is Nov 17, 2026 which is in 86 days.
How were Lotus Eye Hospital And Institute Ltd’s earnings last quarter?
Lotus Eye Hospital And Institute Ltd released its earnings results on Aug 10, 2026. The company reported ₹0.295 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Lotus Eye Hospital And Institute Ltd overvalued?
According to Wall Street analysts Lotus Eye Hospital And Institute Ltd’s price is currently Overvalued.
Does Lotus Eye Hospital And Institute Ltd pay dividends?
Lotus Eye Hospital And Institute Ltd pays a Annually dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Lotus Eye Hospital And Institute Ltd dividends here
What is Lotus Eye Hospital And Institute Ltd’s EPS estimate?
Lotus Eye Hospital And Institute Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lotus Eye Hospital And Institute Ltd have?
Lotus Eye Hospital And Institute Ltd has 20,796,330 shares outstanding.
What happened to Lotus Eye Hospital And Institute Ltd’s price movement after its last earnings report?
Lotus Eye Hospital And Institute Ltd reported an EPS of ₹0.295 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.171%.
Which hedge fund is a major shareholder of Lotus Eye Hospital And Institute Ltd?
Currently, no hedge funds are holding shares in IN:LOTUSEYE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lotus Eye Hospital And Institute Ltd
Lotus Eye Hospital and Institute Limited, a specialty eye care hospital, provides eye care and related services in India. The company offers ReLEx SMILE, a refractive lenticule extraction small incision lenticule extraction; touch free laser; lasik eye surgery; Epi-LASIK, an epithelial laser in situ keratomileusis; Intralase, a blade-free technique to create the corneal flap; Zyoptix Supracor laser technology; robotic femto laser cataract surgery; phacoemulsification; paediatric eye care and squint surgery; and micro incision cataract surgery treatments. It provides treatment services for various eye problems, such as refractive, cataract, glaucoma, retinal disease/diabetic eye care, neuro ophthalmology, binocular vision, and cornea infections, as well as various eye related courses. The company was formerly known as Lotus Eye Care Hospital Limited and changed its name to Lotus Eye Hospital and Institute Limited in April 2013. Lotus Eye Hospital and Institute Limited was founded in 1989 and is based in Coimbatore, India.
Technical Analysis
Apollo Hospitals Enterprise Limited
―
Aster DM Healthcare Ltd.
―
Fortis Healthcare Ltd.
―
Max Healthcare Institute Ltd
―
Global Health Limited
―